Effects of Prior 5-hydroxytryptamine Exposure on Rat Islet Insulin Secretory and Phospholipase C Responses
Overview
Affiliations
Glucose-induced insulin secretion is inhibited by 5-hydroxytryptamine (5HT). In the present studies the specificity of 5HT inhibition of release and the potential biochemical mechanisms involved were investigated. Dose-dependent inhibition of 15 mM glucose-induced secretion was induced by a prior 3 h incubation with 5HT. At the highest 5HT concentration (500 microM) employed, both first and second phase responses to 15 mM glucose were reduced 50-60%. In addition, this level (500 microM) of 5HT virtually abolished 10 mM glucose-induced secretion. In contrast, secretion in response to the protein kinase C activator phorbol 12-myristate 13-acetate (500 nM) was immune to 500 microM 5HT pre-treatment. Glucose usage rates were comparable in both control and 500 microM 5HT-pretreated islets. However, the generation of inositol phosphates and the efflux of 3H-inositol from 3H-inositol-prelabeled islets in response to stimulatory glucose were impaired in parallel with insulin secretion. Based on these observations the following conclusions were reached: (1) 5HT impairs glucose-induced insulin release by altering glucose-induced activation of phospholipase C. (2) Biochemical events distal to phospholipase C remain intact despite this proximal biochemical lesion. (3) Amperometric analysis of 5HT release from 5HT-pretreated islets must take into consideration its profound adverse impact on glucose-induced insulin secretion.
Wu W, Zhi H, Feng W, Jiang L, Yang L, Qian L Acta Pharmacol Sin. 2024; 46(3):687-701.
PMID: 39472495 PMC: 11845781. DOI: 10.1038/s41401-024-01401-w.
Grajales D, Vazquez P, Ruiz-Rosario M, Tuduri E, Mirasierra M, Ferreira V Diabetologia. 2021; 65(3):490-505.
PMID: 34932133 PMC: 8803721. DOI: 10.1007/s00125-021-05630-0.
Jing M, Wang S, Li D, Wang Z, Li Z, Lu Y Front Pharmacol. 2021; 12:761966.
PMID: 34803706 PMC: 8602196. DOI: 10.3389/fphar.2021.761966.
Cataldo L, Suazo J, Olmos P, Bravo C, Galgani J, Fex M J Diabetes Res. 2019; 2019:2714049.
PMID: 31192261 PMC: 6525868. DOI: 10.1155/2019/2714049.
5HTTLPR Polymorphism Affects Insulin Secretion in Patients with Polycystic Ovary Syndrome.
Senk B, Goricar K, Kravos N, Jensterle Sever M, Janez A, Dolzan V Int J Endocrinol. 2018; 2018:6130487.
PMID: 30123264 PMC: 6079412. DOI: 10.1155/2018/6130487.